Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03536637 · ClinicalTrials.gov registry record · Phase 2
DMT310-001 Topical in the Treatment of Acne Vulgaris
A Phase 2 study, sponsored by Dermata Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 121
- Enrollment target
NCT03536637 is a Phase 2 study that has completed, run by Dermata Therapeutics. The registered enrollment target is 121 participants.
The verdict
NCT03536637, a Phase 2 study, has completed, sponsored by Dermata Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 121 participants
- Enrollment target
Study Summary
The objective is to evaluate the tolerability, safety, and efficacy of DMT310 topical powder mixed with diluent in male and female patients with moderate to severe facial acne vulgaris.
Interventions
- DRUG Placebo
- DRUG Hydrogen Peroxide
- DRUG DMT310
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2018-05-22 |
| Est. Completion | 2019-01-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03536637
The ClinicalTrials.gov registry entry for NCT03536637 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dermata Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03536637 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03536637 about?
NCT03536637 is a clinical study titled "DMT310-001 Topical in the Treatment of Acne Vulgaris". The objective is to evaluate the tolerability, safety, and efficacy of DMT310 topical powder mixed with diluent in male and female patients with moderate to severe facial acne vulgaris.
What is the current status of trial NCT03536637?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 121 participants. The study started on 2018-05-22. Estimated completion is 2019-01-28.
What interventions are being tested in trial NCT03536637?
The interventions under investigation include: Placebo (DRUG), Hydrogen Peroxide (DRUG), DMT310 (DRUG).
Who is sponsoring clinical trial NCT03536637?
This trial is sponsored by Dermata Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.